---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Diagnosis"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Diagnosis. Topics: Clinical diagnosis with biopsy in doubtful cases; Clinical assessment: body surface area, PASI, PGA, and DLQI; Psoriasis Area and Severity Index: origin; Measures of disease activity: PASI, PGA, body surface area, and DLQI; 7 further topics. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/diagnosis"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Clinical diagnosis with biopsy in doubtful cases

> “In most subjects, the diagnosis was made according to clinical manifestation, while in doubtful cases, a histopathological assessment of skin biopsies was performed.”

Source: [Jaworecka et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8304988/)

<a id="topic-2.2.1.5-2"></a>

### Clinical assessment: body surface area, PASI, PGA, and DLQI

> “Psoriasis is assessed by the extent of skin involvement (body surface area (BSA)) and the severity of erythema, induration and scaling. In secondary care, validated scores such as Psoriasis Area Severity Index (PASI) and Physician Global Assessment Scale are routinely used along with patient reported outcome measures such as Dermatology Life Quality Index (DLQI).”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.5-3"></a>

### Psoriasis Area and Severity Index: origin

> “The clinical efficacy was evaluated by means of a new index, psoriasis area and severity index (PASI) based on severity and area of psoriatic lesions.”

Source: [Fredriksson and Pettersson (1978)](https://pubmed.ncbi.nlm.nih.gov/357213/)

<a id="topic-2.2.1.5-4"></a>

### Measures of disease activity: PASI, PGA, body surface area, and DLQI

> “Although it has its drawbacks, the most established parameter to measure the severity of skin symptoms in patients with psoriasis is the Psoriasis Area and Severity Index (PASI), which was first introduced in 1978 as an outcome measure in a retinoid trial.”
> “A physician global assessment (PGA) score to evaluate disease severity can be beneficial in daily clinical care in order to rapidly assess the severity of psoriasis. It is important to note that different PGAs exist and that they may differ in the way they are defined and scales that are used. An estimate of the percentage of the affected body surface area (BSA) is also used as a means to measure disease severity.”
> “So far, the Dermatology Life Quality Index (DLQI) has been the most commonly used score for assessing the impact of psoriasis on HRQoL.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.1.5-5"></a>

### Body surface area estimated by palm count

> “In the 2003–2006 cycles, psoriasis severity was assessed by a question about current patches that could be covered by the respondent’s palm, where one palm corresponded to 1% body surface area (BSA)”

Source: [Helmick et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4653077/)

<a id="topic-2.2.1.5-6"></a>

### Limitations of PASI and other clinical severity measures: systematic review of 53 measures

> “The purpose of this study was to identify all clinical measures of psoriasis severity and outcome in use and to evaluate the quality of these measures using clinimetric criteria; we identified 53 separate clinical measures, which were regrouped into 11 measures for quality analysis.”
> “The Psoriasis Area and Severity Index is the most commonly used clinical measure in research, but it has substantial limitations such as low response distribution, no consensus on interpretability, and low responsiveness in mild disease.”

Source: [Spuls et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20043014/)

<a id="topic-2.2.1.5-7"></a>

### Reliability of PASI, body surface area, and PGA

> “In all 3 scales the ICCs were > 0.75, indicating high intra-rater reliability. The highest ICC was for the BSA (0.96) and the lowest one for the PGA (0.87). The CV for the PGA and PASI were 29.3 and 36.9, respectively, indicating moderate inter-rater variability. The CV for the BSA was 57.1, indicating high inter-rater variability.”

Source: [Bożek and Reich (2017)](https://pubmed.ncbi.nlm.nih.gov/29068583/)

<a id="topic-2.2.1.5-8"></a>

### Five-point Investigator's Global Assessment scale

> “The Psoriasis Area and Severity Index (PASI) score is most widely used as a primary endpoint in clinical trials, although it is not routinely used in clinical practice.”
> “The 5-point IGA has a more stringent definition for a score of 1 ("almost clear") compared with 6-point IGA/Physician's Global Assessment (PGA) tools used in previous trials of other biologics in moderate-to-severe psoriasis.”

Source: [Langley et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24354461/)

<a id="topic-2.2.1.5-9"></a>

### Dermatology Life Quality Index score bands

> “DLQI scores 0-1 = no effect on patient's life (GQ = 0, n = 754); DLQI scores 2-5 = small effect on patient's life (GQ = 1, n = 611); DLQI scores 6-10 = moderate effect on patient's life (GQ = 2, n = 327); DLQI scores 11-20 = very large effect on patient's life (GQ = 3, n = 242); DLQI scores 21-30 = extremely large effect on patient's life (GQ = 4, n = 59)”

Source: [Hongbo et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16185263/)

<a id="topic-2.2.1.5-10"></a>

### Severity classification: mild and moderate-to-severe definitions with upgrade criteria

> “Currently, the disease definition most commonly used for psoriasis is strongly influenced by the definition used in clinical trials. It was thoroughly discussed and formally agreed upon in a European consensus project in 2011.”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

| Category | Definition |
| --- | --- |
| Mild psoriasis | “BSA ≤ 10 and PASI ≤ 10 and DLQI ≤ 10” |
| Moderate to severe psoriasis | “(BSA > 10 or PASI > 10) and DLQI > 10” |
| Criteria to upgrade mild disease to moderate-to-severe | “major involvement of visible areas, major involvement of the scalp, involvement of the genitals, palms of hands or soles of feet, onycholysis or onychodystrophy of at least two fingernails, pruritis leading to scratching, and presence of recalcitrant plaques.” |
| Particularly severe psoriasis | “Criteria for particularly severe psoriasis include PASI ≥ 20, DLQI ≥ 15; rapid deterioration of findings, severe involvement of hands and/or feet, scalp, face, nails, or genitals.” |

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.1.5-11"></a>

### Severity classification: topical or systemic candidacy

> “This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy.”

Source: [Strober et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31425723/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
